For patients with chronic myeloid leukemia who become or are inherently resistant to imatinib therapy, including dose escalation, several important factors must be considered when deciding which strategy to attempt next. The second-generation tyrosine kinase inhibitors (TKIs) dasatinib and nilotinib offer improved potency and a high likelihood of success for these patients. Overall, the efficacy data are comparable for these two agents, and so physicians should consider the BCR-ABL mutation profile and the patient's history to make an educated decision on the best choice. Only a few BCR-ABL mutations seem to be less responsive to either nilotinib or dasatinib and it is recommended to choose the second-line TKI that has shown clinical activity against the specific mutation in these cases. For patients with all other mutations, and for patients with no mutations, it is recommended to choose the second-generation TKI based on the patient's disease history. It is important to choose an agent that minimizes the likelihood of exacerbating the patient's past tolerability issues to imatinib, or comorbid conditions. Here, we propose a treatment algorithm for imatinib-resistant patients based on BCR-ABL mutation status and patient history.
Introduction

CML in the imatinib era
The instigating factor in the pathogenesis of chronic myeloid leukemia (CML) is the formation of the Philadelphia chromosome (Ph, 22q-) resulting from the reciprocal translocation between chromosomes 9 and 22 (t(9;22)(q34;q11)), which is associated with the de novo creation of the BCR-ABL fusion oncogene. 1, 2 The gene product of the BCR-ABL gene is a constitutively active rogue version of the ABL tyrosine kinase. Typically, this kinase carefully regulates downstream targets, including c-Myc, Akt and Jun, all of which are seminal to the proliferation and survival of normal cells. However, the hyperactivity of the BCR-ABL kinase disrupts this fine balance and pushes the cells toward uncontrolled proliferation and survival, both of which provide a growth advantage to the malignant cells bearing this mutation, ultimately leading to the pathogenesis of CML. [3] [4] [5] Imatinib mesylate (Gleevec/Glivec formerly STI571; Novartis Pharmaceuticals, East Hanover, NJ, USA) is a rationally designed tyrosine kinase inhibitor (TKI) that blocks the ATPbinding site of BCR-ABL, thereby suppressing downstream signaling. 6 Several studies have established the efficacy and safety of imatinib, which is currently recommended as the firstline therapy for CML in chronic phase (CML-CP) by the National Comprehensive Cancer Network and European LeukemiaNet (ELN), and is thus accepted as the standard of care in common practice. 7, 8 Recent 6-and 7-year updates of the phase 3 International Randomized Study of Interferon and STI571 (IRIS) trial confirmed the long-term efficacy and safety of imatinib. 9, 10 After 7 years, the cumulative complete cytogenetic response (CCyR) rate for first-line imatinib-treated patients was 82%. The event-free survival was 81%, and the estimated rate of freedom from progression to accelerated phase (AP) or blastic phase was 93%. The estimated overall survival rate for patients treated with imatinib was 86%. At 7 years, 332 patients (60%) randomized to imatinib remained on treatment. Of the 40% (n ¼ 221) of patients who discontinued the study drug, 68% were still alive at 7 years (note that some patients continued imatinib off study). 10 Nonetheless, in some patients, resistance to imatinib can occur. Results from the IRIS trial showed a peak of imatinib resistance, defined as the loss of hematological or major cytogenetic response, advanced disease or death in the second and third years of therapy with 7.5 and 4.8%, respectively, which gradually decreases to o2% thereafter. 10 A common reason for resistance to imatinib observed in about 50% of cases in CP is the development of point mutations in the BCR-ABL kinase domain. Point mutations, especially in the BCR-ABL ATPbinding site, result in resistance by preventing imatinib binding at the active site of the enzyme. Other mechanisms of resistance owing to intrinsic factors include: BCR-ABL gene amplification, BCR-ABL overexpression, aberrations in other oncogenetic signaling pathways, and the persistence of leukemic stem cells. [11] [12] [13] Extrinsic factors contributing to resistance include those that decrease the blood levels or bioavailability of imatinib, such as patient compliance, drug-drug interactions, drug influx and efflux and multidrug resistance in sanctuary sites, as well as microenvironmental factors. 13 Imatinib dose escalation is typically the first option for CML-CP patients with cytogenetic resistance or relapse to 400 mg/day imatinib. Support for imatinib dose escalation is provided in a retrospective analysis of imatinib patients dose escalated in the IRIS trial.
14 Dose escalation was allowed for patients who did not achieve a complete hematological response (CHR) by 3 months or a minor CyR (minCyR; Ph þ 36-65%) by 12 months, and for patients who lost a major CyR (MCyR; Ph p35%) at any time, or who progressed (including increase in white blood cell count). Importantly, no dose escalation was specified for patients who lost a CCyR. A dose increase to 600-800 mg/day was reported for 106 out of 551 (19%) patients enrolled in the SPOTLIGHT study. Dose escalations were based on IRIS protocol criteria for 39 of these patients and on ELN 2006 recommendations for 48 of these patients. For patients escalated according to IRIS protocol criteria, responses included six of seven patients achieving CHR at 3 months, who had never achieved CHR on imatinib 400 mg/day therapy, and two of whom attained a CCyR with dose escalation. Of the eight patients who had not achieved a minCyR at 12 months on 400 mg/day imatinib, four patients (50%) achieved a CCyR with dose escalation. Among 18 patients who lost an MCyR on imatinib 400 mg/day, nine patients (50%) re-achieved an MCyR within 12.5 months of imatinib dose escalation; a CCyR was attained by three (25%) of them. Clinical responses were achieved within 12 months for 21 out of 48 (44%) patients dose escalated per ELN recommendations with 6 out of 11 (55%) achieving MCyR within 12 months of dose escalation and 2 out of 10 (20%) patients with failure at 18 months attaining CCyR 12 months after dose increase. For the entire cohort of 106 patients who had imatinib dose escalation, the estimated progression-free survival (PFS) was 89% and the overall survival was 84% at 36 months after escalation of imatinib dose. 14 In another study, 84 patients with CML-CP were dose escalated to imatinib 600-800 mg/day after hematological (n ¼ 21), or cytogenetic failure (resistance: n ¼ 30; relapse: n ¼ 33) to imatinib 400 mg/day. 15 Unlike the IRIS dose escalation criteria, this study allowed patients who lost a CCyR to be dose escalated. Among patients who met the criteria for cytogenetic failure, 75% (47 of 63) responded to imatinib dose escalation. Patients who had never achieved a previous cytogenetic response on standard-dose imatinib showed less favorable outcomes than did patients who had previously attained a CyR, with 2-year event-free survival rates of 44 vs 74%, and 3-year event-free survival rates of 30 vs 66%, respectively. For patients who were dose escalated because of the loss of hematological response, 48% achieved a CHR and 3 out of 21 (14%) attained a CyR after imatinib dose increase. Overall, the responses to imatinib dose escalation therapy were durable, with a sustained MCyR in 74% of patients at 3 years. Furthermore, the median duration of MCyR was 5 years. Treatment was well tolerated with 76% of patients receiving 100% of their intended imatinib dose at 12 months. Taken together, the results from these studies suggest that imatinib dose escalation is effective in patients with CML-CP with cytogenetic resistance or relapse to imatinib 400 mg/day.
Optimizing responses through careful monitoring and active adverse event management
Approximately 14% of patients with CML-CP in the IRIS trial, including those who were dose escalated, either discontinued imatinib treatment or crossed over to an alternative treatment because of the lack of efficacy or progression. 9, 10 To proactively identify patients with suboptimal responses or resistance to imatinib, several important levels of monitoring are recommended.
Monitoring of the bone marrow for cytogenetic response is recommended at 3, 6 and 12 months. 7, 16 If a patient shows a CCyR, then bone marrow testing can be performed annually. In the case of stable major molecular response (MMR) and no other need to change therapy, bone marrow aspirations can be omitted. Peripheral blood should be collected and analyzed for BCR-ABL transcript levels every 3 months within the first 12 months of treatment. If an MMR is observed, the frequency of monitoring can occur every 6 months. In the event of increases in transcript levels, the level at which the change occurs should be considered, as the accuracy of the test does depend on the amount of residual BCR-ABL transcripts. 16 The National Comprehensive Cancer Network recommends the following monitoring schedule: any 1-log increase in BCR-ABL transcripts should be repeated in 1 month; if the increase is confirmed on subsequent sampling, the frequency of monitoring should be increased from every 3 months to every month; and mutation assays can be considered in case of elevations in BCR-ABL transcripts. Monitoring of mutations is becoming an increasingly important area of research entering clinical practice, and investigation to potentially determine the best therapeutic approach to treat patients in the second-line setting will be discussed in more detail below.
Management of adverse events (AEs) is another important factor in maximizing the efficacy of CML therapy. The successful and proactive management of AEs helps maximize dose intensity and may thereby optimize response to imatinib. Both hematological and nonhematological AEs occurring on imatinib therapy were mainly mild to moderate in severity, and were frequently transient or self-limiting. Most AEs were manageable through routine clinical intervention and palliative care, although some cases may require dose adjustments, including dose reduction, interruption or discontinuation. The management of AEs in CML-CP patients has been reviewed extensively elsewhere. 17 Strategies for overcoming the probability of resistance or suboptimal response to imatinib therapy in the frontline setting
High-dose imatinib (800 mg/day)
To explore the possibility that standard-dose imatinib might actually be optimized for patients at higher starting doses, trials examining high-dose imatinib, including the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study and the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) 021/ELN high-dose imatinib trials, were conducted. The TOPS study is a phase 3 trial comparing the efficacy and safety of high-dose (800 mg/day) with standard-dose imatinib (400 mg/day) in patients with newly diagnosed CML-CP. 18 The primary end point of the study was rate of MMR at 12 months of therapy. The CCyR rates at 6 months were significantly higher with imatinib 800 mg/day (57%) compared with imatinib 400 mg/day (45%). However, by 12 months, this difference was no longer significant. Likewise, the MMR rates at 12 months were 46% with 800 mg/day vs 40% with imatinib 400 mg/day, but the difference was not significant. It is noted that patients receiving imatinib 800 mg/day achieved MMRs faster compared with those receiving imatinib 400 mg/day. A trend toward higher rates of MMR at 12 months among high-risk Sokal score patients receiving 800 mg/day (41%) vs 400 mg/day (26%) was observed (P ¼ 0.1565). Importantly, 5.6 vs 1.3% of patients had to discontinue imatinib therapy in the 800 and 400 mg arms, respectively, because of side effects. There was a trend toward more grade 3/4 myelosuppression with 800 mg imatinib compared with the standard 400 mg dose.
The TOPS results were confirmed in a randomized trial (021/ELN) assessing the efficacy of imatinib 800 vs 400 mg/day as frontline therapy in high-risk Sokal patients. 19 The primary study end point of CCyR at 1 year was not significantly different between patients treated with imatinib 400 mg/day (61%) vs 800 mg/day (64%). There was a trend toward higher rates of MMR with 800 mg/day compared with 400 mg/day, but the differences were not statistically significant. A relationship
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Weighing TKI efficacy and safety with BCR-ABL mutations and CML patient history E Jabbour et al 7 between imatinib dose and CCyR was observed in this study. Of the 87 patients in the 400 mg arm receiving 4350 mg of imatinib, 72% achieved CCyR. Likewise, in the 800 mg imatinib arm, 23 out of 24 (96%) patients who received 800 mg daily achieved CCyR, and 26 out of 34 (76%) patients receiving 4600 mg daily achieved CCyR. AEs were not significantly different between treatment arms, but compliance was lower in the 800 mg arm (62% received doses 4600 mg) compared with the 400 mg arm (87% received doses 4350 mg).
Nilotinib and dasatinib in the frontline setting Nilotinib (Tasigna formerly AMN107, Novartis Pharmaceuticals) was designed to interact with the same inactive conformation of BCR-ABL as that targeted by imatinib, but to be a more potent and selective inhibitor. [20] [21] [22] Three ongoing studies, including a randomized phase 3 trial, are investigating the use of nilotinib in the frontline setting.
Data from the MD Anderson Cancer Center study show high rates of cytogenetic and molecular responses (including complete molecular responses) in newly diagnosed CML-CP patients treated with nilotinib 400 mg twice daily. 23 Nearly all patients (93%) experienced rapid CCyR (within 3 months) with 100% of patients achieving CCyR at 6 months. Nearly half (45%) of the patients investigated achieved early MMR within 6 months. Both CCyR and MMR were maintained for 12 months. Confirmed complete molecular response was reported in 5% of patients at 12 months. The primary end point of MMR at 12 months was observed in 52% of patients, which is similar to that for high-dose (800 mg/day) imatinib (47%) in a study conducted previously at the MD Anderson Cancer Center. Rates of grade 3/4 hematologic and nonhematologic AEs were low and comparable with the safety profile of nilotinib in CML-CP patients with imatinib-resistant or -intolerant disease. In another phase 2 study of nilotinib in newly diagnosed CML-CP patients conducted by the GIMEMA working party, nilotinib treatment resulted in rapid rates of CCyR, with 78 and 96% of patients achieving CCyR at 3 and 6 months, respectively. 24 Among patients who experienced CCyR, 59 and 74% achieved an MMR at 3 and 6 months, respectively. Severe hematological toxicities were rare, and elevated bilirubin was the primary cause for dose reduction. Overall, toxicities were minimal and mostly grade 1, resulting in no dose interruptions and preserved quality of life. The data from both of these studies support the ongoing phase 3 randomized study of nilotinib (300 or 400 mg twice daily) vs imatinib 400 mg/day in newly diagnosed CML-CP patients (Evaluating Nilotinib Efficacy in Clinical Trials of Newly Diagnosed Ph þ CML Patients (ENESTnd) Trial).
Dasatinib (Sprycel formerly BMS-354825, Bristol-Myers Squibb, New York, NY, USA) is a potent BCR-ABL kinase inhibitor that binds both active and inactive conformations of the ABL kinase domain. 25 Dasatinib in the frontline setting is also being studied in two ongoing studies. The first study, being conducted at the MD Anderson Cancer Center, is similar in design to the nilotinib study described above, and also includes once daily vs twice daily dosing schedules of dasatinib (100 mg/day). 26 Most patients received the planned dose of 100 mg/day with either schedule. To date, high cytogenetic and molecular responses have been observed with dasatinib therapy. Of 35 patients with at least 12 months of follow-up, 97% have achieved CCyR, 34% achieved MMR, and 2% achieved confirmed complete molecular response. No differences in dasatinib efficacy by administration schedule (once daily vs twice daily) were observed. The AE profile of dasatinib in this setting was tolerable. Results from this study will support the results of the ongoing multicenter randomized phase 3 trial (NCT00481247) of dasatinib once daily vs imatinib 400 mg/day in newly diagnosed CML-CP patients.
In the event of first-line failure, how should one choose a second-generation TKI?
Dasatinib
Dasatinib 70 mg twice daily was approved in 2006 for the treatment of patients with CML-CP, -AP and -BC (blast crisis) with resistance or intolerance to imatinib and for Ph þ acute lymphoblastic leukemia patients resistant or intolerant to previous therapy. 27 More recently, dasatinib was also approved for oncedaily dosing at 100 mg in CML-CP patients. 28 Dasatinib was registered for the treatment of CML-CP based on results from the SRC/ABL Tyrosine kinase inhibition Activity Research Trials of dasatinib (START)-C trial, a phase 2 international study of dasatinib 70 mg twice daily that included 387 CML-CP patients with resistance (n ¼ 288) or intolerance (n ¼ 99) to imatinib. 29 Recent 24-month follow-up data showed a 2-year MCyR rate of 62% and a CCyR rate of 53%. 30 The PFS at 2 years was 80% and the overall survival rate was 94%. Grade 3/4 thrombocytopenia and neutropenia were documented for 49 and 50% of patients, respectively. Pleural effusions occurred in 26% of patients overall, with 9% experiencing severe AEs. Bleeding was reported in 16% of patients, with 4% experiencing severe AEs.
The efficacy of dasatinib in patients with CML-CP was also studied in the START-R trial in which patients with failure on imatinib 400-600 mg daily were randomized on a 2:1 basis to receive either dasatinib (70 mg twice daily, n ¼ 101) or highdose imatinib (800 mg/day, n ¼ 49). 31 After a minimum follow-up of 24 months, 31 53% of patients in the dasatinib arm achieved an MCyR compared with 33% in the high-dose imatinib arm. A CCyR was noted in 44% of patients in the dasatinib arm compared with 18% in the imatinib arm, and 29% of dasatinib-treated patients achieved an MMR compared with 12% of imatinib-treated patients. PFS at 24 months favored dasatinib over dose escalation of imatinib (86 vs 65%, P ¼ 0.0012). Although a statistically significant (P ¼ 0.0033) increase in PFS was observed for patients switching from 600 mg/day imatinib to dasatinib, the difference in PFS was not significant for patients switching from 400 mg/day imatinib to dasatinib (P ¼ 0.052). When considering only patients who dose escalated from 400 to 800 mg/day imatinib, an MCyR rate of 50% was achieved. Toxicity in the dasatinib arm was higher compared with the high-dose imatinib arm, with thrombocytopenia reported in 63 vs 39% of patients, and neutropenia observed in 57 vs 14%, respectively. In the dasatinib arm, severe pleural effusions were reported in 5% of patients. Severe bleeding was similar in both arms.
Recently, dasatinib was approved for 100 mg once-daily dosing for patients with CML-CP based on results from a doseoptimization study (Study CA180-034). 32 Patients with CML-CP who received dasatinib 100 mg once daily achieved comparable MCyR rates as patients who received dasatinib 70 mg twice daily; however, survival was significantly better with dasatinib 100 mg once daily, perhaps because of less treatment interruptions and discontinuations and better tolerability of the intermittent BCR-ABL inhibition.
Nilotinib
Nilotinib was approved in 2007 for patients with CML-CP and -AP with resistance or intolerance to previous therapy including
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Weighing TKI efficacy and safety with BCR-ABL mutations and CML patient history E Jabbour et al 8 imatinib. 33 The safety and efficacy of nilotinib has been evaluated in a phase 2 multicenter international trial. 34 Adults with imatinib-resistant or -intolerant CML-CP were treated with 400 mg nilotinib twice daily. Among CML-CP patients without CHR at baseline, CHR was achieved in 76% of patients and MCyR was achieved in 51% of patients. 34 Of patients with a baseline CHR, 73% achieved MCyR. Overall, CCyR was achieved in 44% of patients. Hematological response and MCyR occurred rapidly, with a median time of one month to attain a CHR and a median time of 2.8 months to achieve an MCyR. Among the 189 patients who achieved an MCyR, 78% maintained an MCyR at 24 months. At 24 months, 64% of CML-CP patients remained free of disease progression. The estimated overall survival rate at 24 months was 88%. The AEs of patients on nilotinib therapy were mild to moderate with myelosuppression being the most commonly reported grade 3/4 AEs. 34 Rates of thrombocytopenia, neutropenia and anemia were 31, 31 and 10%, respectively. Pleural or pericardial effusions were observed in only 1% of CML-CP patients and none were severe.
Nilotinib and imatinib were found to have minimal crossintolerance, defined as the occurrence of any grade 3/4 or persistent grade 2 nilotinib-induced toxicity previously reported in the same patient receiving imatinib. 35 Cross-intolerance of nonhematologic AEs was rare and cross-intolerance owing to hematologic AEs was infrequent. Thrombocytopenia was the only cross-intolerant AE that led to nilotinib discontinuation in some patients who had previously experienced severe thrombocytopenia while taking imatinib.
Impact of BCR-ABL mutations on efficacy of second-line TKIs
A number of analyses have been conducted to determine the response rates of patients with various BCR-ABL mutations to second-generation TKIs. A recent study of 581 imatinib-resistant or -intolerant patients from the dasatinib dose-finding study (35% with baseline mutations) examined the correlation between baseline imatinib-resistant BCR-ABL mutations and response to dasatinib 70 mg twice daily in CML-CP. 36 Dasatinib was efficacious regardless of most mutations and results did not differ significantly across dasatinib doses. Overall, only a subgroup of patients showed mutations that were less sensitive to dasatinib (Q252H, E255K/V, V299L and F317L).
A recent analysis of imatinib-resistant CML-CP patients was conducted to assess patients for the occurrence of baseline BCR-ABL mutations and to determine the impact of those mutations after 12 months of nilotinib therapy. 37 Hematological and cytogenetic response rates to nilotinib were similar regardless of the presence or absence of most mutations. However, it was observed that patients with E255K/V, Y253F/H or F359C/V mutations had less favorable outcome with nilotinib therapy.
These studies show that patients without mutations before second-generation TKIs, and most patients with mutations, have similar response and progression rates on nilotinib or dasatinib therapy. 36, 37 These results also suggest that very few patients show baseline mutations in BCR-ABL, subsequent to imatinib resistance, that have overlapping resistance to both nilotinib and dasatinib.
The T315I mutation is the least responsive mutation to imatinib, dasatinib or nilotinib with median inhibitory concentrations (IC 50s ) of 46400, 4200 and 42000 nM, respectively. 38 For patients with the T315I mutation, switching to an investigational agent may be the best option. Investigational agents, such as MK-0457, ON01910, ON12380, XL-228 and PHA739358, which target regions outside the ATP-binding site of BCR-ABL, may be more effective against the T315I mutant. 39 Further, nonspecific agents such as omacetaxine (homoharringtonine) have been investigated, 40 but the selective effect on SPOTLIGHT Figure 1 Treatment approach for patients with chronic myeloid leukemia in chronic phase (CML-CP). CyR, cytogenetic response; CCyR, complete cytogenetic response; CHR, complete hematological response; COPD, chronic obstructive pulmonary disease; MCyR, major cytogenetic response; minCyR, minor cytogenetic response; TKI, tyrosine kinase inhibitor.
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Impact of patient history on safety and tolerability of second-line TKIs
Although imatinib-intolerant and -resistant patients respond well to dasatinib or nilotinib, the potential impact of the drug's AE profile on any of the patient's preexisting conditions should be considered in choosing between second-generation BCR-ABL inhibitors.
Although pleural effusion is more common for patients receiving dasatinib therapy, patients with risk factors for pleural effusion such as chronic obstructive pulmonary disease and hypertension are at greater risk for developing these complications. 41 Risk factors for developing pleural effusion while taking dasatinib also include disease stage (BC4AP4CP), previous lung problems such as smoking or infections and those patients maintained on starting doses of dasatinib. 42 Blood glucose elevations have been observed in 11% of CML-CP and 4% of CML-AP patients treated with nilotinib. 33 Although no CML-CP or CML-AP patients required dose adjustments, dose interruption or discontinued nilotinib therapy owing to elevated blood glucose, or preexisting hyperglycemia should be carefully monitored to ensure that the condition is not exacerbated by nilotinib treatment. Previous severe pancreatitis may also be a matter of concern regarding nilotinib therapy, and patients with a history should be closely monitored on nilotinib therapy.
Cardiac events, including congestive heart failure, left ventricular dysfunction and QT prolongation, have all been reported with dasatinib and nilotinib. 27, 33 Though they occurred in o5% of the patient population, a literature review of clinical trials in CML-CP for dasatinib 70 mg twice daily and nilotinib 400 mg twice daily revealed grade 3/4 nonhematologic AEs, including arrhythmias, for both agents. 43 There were rare sudden deaths on nilotinib therapy reported in the safety population of the registration study and in the expanded access program, and although not confirmed, ventricular repolarization abnormalities may have contributed to their occurrence. 33 
Summary
A treatment strategy for imatinib-resistant patients is shown in Figure 1 . For those patients who become resistant to imatinib therapy, a strategy of imatinib dose escalation could be considered for patients with cytogenetic resistance or relapse to 400 mg imatinib therapy. For patients with T315I mutant BCR-ABL, the best option is to move to investigational agents that do not rely on active site binding. For patients who never achieved a CyR on standard-dose imatinib therapy or are resistant to imatinib, second-generation TKIsFnilotinib and dasatinibFoffer improved potency. Although no direct comparisons can be made about the efficacy of these two secondgeneration TKIs, given the differences in patient populations enrolled in the pivotal studies, the efficacy data overall are comparable for these two agents. An important minority of BCR-ABL mutations appears to be less responsive to either nilotinib or dasatinib and these should be considered when deciding which agent to use for each individual patient. Overall, the incidence of mutations unresponsive to currently approved second-line treatment is rare and only a handful of mutations have been identified that lead to less favorable responses to treatment with dasatinib or nilotinib ( Table 1) .
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